Pfizer: Undervalued, Investment Opportunity!

Pfizer Inc. (NYSE:PFE) stands out as one of the undervalued long-term stocks currently available for purchase. On October 19, Pfizer and Astellas Pharma US Inc. announced the final overall survival results of the Phase 3 EMBARK study.

In this study, the effect of the drug XTANDI in combination with leuprolide was evaluated as a standalone treatment in men with non-metastatic hormone-sensitive prostate cancer. The results obtained showed that the risk of death was reduced by 40.3% with this treatment method compared to the use of leuprolide alone. Additionally, the average follow-up duration for the combination of XTANDI and leuprolide was determined to be 94.2 months. The safety profile of the treatment was consistent with those observed in the objective EMBARK analysis.

Pfizer's Vice President of Oncology, Dr. Johanna Bendell, emphasized the critical importance of early intervention with an effective treatment in men with high-risk recurrence: "In men with high-risk recurrence, there is up to a 90% risk of developing metastatic disease. The final analysis from EMBARK demonstrates that the combination of XTANDI and leuprolide extends patients' survival and significantly improves outcomes."

Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of medicines. While acknowledging PFE's potential among investment opportunities, we note that some artificial intelligence stocks may offer higher returns and carry less risk. If you are looking for a highly undervalued artificial intelligence stock that can benefit from Trump-era tariffs and the advantages of reshoring, we recommend our free report on the best short-term artificial intelligence stocks.